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The most common cause of acute kidney injury (AKI) in hospitalized patients is sepsis. However, the molecular
pathways and mechanisms that mediate septic AKI are not well defined. Experiments performed over the past
20 years suggest that there are profound differences in the pathogenesis between septic and ischemic AKI. Septic
AKI often occurs independently of hypoperfusion, and is mediated by a concomitant pro- and anti-inflammatory
state that is activated in response to various pathogen-associated molecular patterns, such as endotoxin, as well as
damage-associated molecular patterns. These molecular patterns are recognized by Toll-like receptors (TLRs) found
in the kidney, and effectuate downstream inflammatory pathways. Additionally, apoptosis has been proposed to
play a role in the pathogenesis of septic AKI. However, targeted therapies designed to mitigate the above aspects
of the inflammatory state, TLR-related pathways, and apoptosis have failed to show significant clinical benefit. This
failure is likely due to the protean nature of septic AKI, whereby different patients present at different points along
the immunologic spectrum. While one patient may benefit from targeted therapy at one end of the spectrum,
another patient at the other end may be harmed by the same therapy. We propose that a next important step in
septic AKI research will be to identify where patients lie on the immunologic spectrum in order to appropriately
target therapies at the inflammatory cascade, TLRs, and possibly apoptosis.Introduction
Acute kidney injury (AKI) is a very common and espe-
cially formidable clinical problem in the ICU, where
mortality rates approach 25% and soar to 50 to 60%
when severe enough to require renal replacement ther-
apy [1]. These statistics have not significantly improved
over the past 50 years, though patients today are gener-
ally older and have more comorbidities [1]. The most
common cause of AKI in hospitalized patients is sepsis
[2], and AKI occurs with regularity even in non-severe
sepsis where clinically evident hemodynamic changes
are not readily apparent [3]. The combination of sepsis
and AKI portends a dire clinical situation that is associated
with a hospital mortality rate as high as 70% [4]. However,
the basic pathophysiologic mechanisms undergirding the* Correspondence: pastorn@pitt.edu
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months following its publication. After this time
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medium, provided the original work is properly
(http://creativecommons.org/publicdomain/zeroassociation between sepsis and the clinical manifestations
of AKI are not completely understood.
In this review, we will first summarize the findings of
published human studies that support the concept that
the pathogenesis of septic AKI in humans should not be
exclusively viewed in the context of distributive shock-
associated ischemia, but rather also within the context
of a dysregulated and ill-defined inflammatory response
to septic stimuli. We then discuss why previous attempts
at modulating the inflammatory response in septic AKI
may have failed, and highlight more recent trials and
therapies aimed at targeted treatment based on where
patients lie along the immunologic spectrum. We also dis-
cuss the role Toll-like receptors (TLRs) have been shown
to play in endotoxemic models of AKI, and again focus on
why agents used to block TLR-related pathways may have
failed to show significant clinical benefit. Finally, we review
the data supporting and refuting a central role for apop-
tosis in septic AKI, and argue that much of the clinicalLtd. The licensee has exclusive rights to distribute this article, in any medium, for 12
, the article is available under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any
credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
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death secondary to apoptosis or necrosis.
Septic acute kidney injury: is it hyperemic kidney injury?
The morphologic changes that are seen in classic ischemic
and toxic acute tubular necrosis are often lacking [5,6] or
are microscopically distinct in septic AKI [7,8]. While the
use of renal biopsy in the management of septic AKI is
exceedingly rare in many western nations, most human
studies have found no consistent histopathologic changes
in septic AKI, and acute tubular necrosis is infrequently
observed [5,6]. In a systematic review of six studies
describing histopathologic changes seen in septic AKI,
Langenberg and colleagues [6] found that tubular epithe-
lial cell necrosis was seen in only 22% of human samples
taken after septic injury. A more recent study by Takasu
and colleagues [8] examined post-mortem kidneys taken
from 67 patients who died with sepsis, and while they
found focal tubular injury in 78% of septic kidneys, the
majority of tubular cells were normal.
Perhaps an even greater distinction between non-septic
AKI and septic AKI might be made when examining the
role of overall vascular hemodynamics. Traditionally, sep-
tic AKI has been thought to be secondary to a demand
and perfusion mismatch, whereby renal blood flow was
diminished in the midst of increased metabolic demand
[9,10]. Furthering this idea are the FINNAKI and SEPSIS-
PAM studies, two recently published trials that suggest
septic patients with target mean arterial pressure higher
than 65 mmHg might have less progression to AKI [11]
and less need for renal-replacement therapy if they suffer
from chronic hypertension [12].
Nevertheless, the data directly measuring overall kidney
blood flow during sepsis suggest that flow is increased in
the septic physiologic state. Despite a plethora of conflict-
ing animal studies - some of which show overall increased
kidney blood flow while others show overall decreased
kidney blood flow [10,13] - Langenberg and associates
[13] found only three human studies that have directly
measured renal blood flow in septic AKI by invasive
hemodynamic measurements. All three studies showed
that septic AKI occurs in the midst of renal arterial vaso-
dilation and preserved overall renal blood flow [14-16]. In
another study with a small cohort of 10 patients with
sepsis, renal blood flow was either preserved or in-
creased [17]. Bellomo and associates [18] have thus pro-
posed a new concept for understanding septic AKI
hemodynamics, so-called hyperemic AKI.
Despite the above human studies that suggest an
increase in overall renal blood flow in septic AKI, the
complex interplay between regional microcirculation
and hemodynamics may play a much more important
role in overall kidney function during sepsis. As Langen-
berg and colleagues [13] and Molitoris [19] point out,glomerular filtration rate (GFR) and cellular perfusion
can decrease even if overall renal blood flow is increased
due to disproportionate vascular resistance between the
afferent and efferent arterioles, regional microvascular
flow rates, or renal venous congestion. There are limited
human data regarding microcirculatory function in
septic AKI. However, using implanted laser Doppler flow
probes, Di Giantomasso and colleagues [20] showed that,
in sheep hyperdynamic septic models using Escherichia
coli infusion as a source of infection, regional redistri-
bution of blood flow from the medulla to the cortex was
absent during sepsis. Local inhibition of endothelial nitric
oxide synthase by liposaccharide (LPS) may play a role in
the decreased GFR observed in endotoxemic models of
AKI, at least in rats [21]. In a hyperdynamic endotoxemic
pig model, Cohen and associates [22] likewise observed a
significant increase in overall kidney blood flow after LPS
administration; however, almost all of the increased blood
flow was shunted to the medulla, with no increase in
cortical blood flow. In a sepsis pig model using peritonitis
as a source of infection, Chvojka and colleagues [23] ob-
served that while overall renal blood flow increased in
septic pigs with AKI, renal perfusion pressure significantly
decreased as a result of increased renal venous pressure.
In parallel to this, there was a significant decrease in renal
cortex microvascular perfusion as measured by laser
Doppler blood flow, as well as increased renal venous
acidosis and lactate concentrations [23]. These septic
physiologic observations related to regional kidney blood
flow have been found in humans as well. In a retrospective
observational study, it was shown that elevated central
venous pressure was associated with progression to AKI
in septic patients (odds ratio = 1.22, 95% confidence inter-
val (CI) 1.08 to 1.39), suggesting that venous congestion
may contribute to septic AKI in humans [24].
An in-depth discussion about renal microcirculation in
septic AKI is beyond the scope of this review. As men-
tioned above, there is a dearth of human data on this im-
portant topic and most of the animal data are conflicting
and difficult to interpret, given the different models used
and measurement modalities employed. While it is clear
from above that ischemic and microvascular dysfunction
may contribute to septic AKI, septic AKI can occur inde-
pendently of overall renal hypoperfusion or ischemia [25].
Indeed, AKI occurs in up to one-third of non-critically ill
patients with pneumonia, of which less than 10% received
any vasopressor therapy [3]. Additionally, there have been
many studies published over the past decade showing that
plasma and urinary biomarkers are often distinct in septic
and non-septic AKI (reviewed in [26]). This suggests a
fundamental mechanistic distinction that may involve
primarily a dysregulated immune response and possibly
apoptosis as opposed to ischemic factors related to distri-
butive shock [25].
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For many years, organ damage and other deleterious
sequelae from sepsis were thought to result from a
hyper-inflammatory ‘cytokine storm,’ triggered in response
to either an infectious pathogen or major physiologic
insult [27]. Thus, a significant amount of sepsis research
in the 1990s focused on identifying specific cytokines that
were associated with the stereotypical sepsis syndrome.
However, while cytokines such as TNF-α and IL-1β were
found in very high concentrations in septic patients, large
clinical trials testing specific cytokine inhibition failed to
show any clinical benefit [28,29].
As a consequence of these failed trails, new ideas regar-
ding the pathogenesis and pathophysiology of sepsis
emerged [30]. Utilizing pathologic data showing impaired
immune function in some septic patients, Hotchkiss and
Remick have both hypothesized that the host’s dysregu-
lated and ill-defined inflammatory response to stimuli is
associated with both pro- and anti-inflammatory states
[31-33]. Many septic patients are chronically ill, and their
development of sepsis is not necessarily associated with a
hyper-inflammatory response [31]. One current goal in
sepsis research is to identify where a septic patient lies on
the immunologic spectrum, and identify which patients
will benefit from specific therapies.
Indeed, the early trials focusing on inhibiting TNF-α
or IL-1β did not risk-stratify their patients in terms of
their individual inflammatory status or genetic predilec-
tions towards certain types of phenotypic responses
[28,29]. It seems likely that the next step in sepsis and
septic AKI treatment will be targeted therapy based on
stratification of patients that have a higher likelihood of
responding to various treatments. Panacek and colleagues
first attempted this strategy with a randomized controlled
trial to study afelimomab, an anti-TNF F(ab’)2 monoclonal
antibody fragment, in septic patients with and without
elevated serum levels of IL-6 [34]. In this study, for those
patients who had serum IL-6 levels >1,000 pg/mL, they
demonstrated a 4% absolute risk reduction in mortality at
28 days after treatment in patients treated with the agent
than in those not treated. Although rates of kidney failure
were not reported in this trial, there was a statistically
significant improvement in the overall Sequential Organ
Failure Assessment (SOFA) score starting at 48 hours after
drug administration.
As an alternative to targeted treatment, some resear-
chers have proposed implementing treatment strategies
that are able to broadly regulate the overall inflammatory
response in sepsis by using extra-corporeal blood purifica-
tion. Multiple in vitro and rat in vivo studies have demon-
strated that the broad reduction of inflammatory cytokines
by hemoadsorption can protect against renal and liver
injury [35], improve bacterial clearance [36] and mean
arterial pressure [37], decrease apoptosis and tubular celldamage [38], and improve overall survival [35,37]. How-
ever, its efficacy in humans is still unknown. The Early Use
of Polymyxin B Hemoperfusion in Abdominal Sepsis
(EUPHAS) trial showed improved hemodynamics, organ
function, and 28-day mortality in patients suffering from
severe sepsis or septic shock from intra-abdominal Gram-
negative infections who were treated with two sessions of
polymyxin B hemoperfusion compared with controls [39].
Renal SOFA scores improved in the treatment group (-0.3,
95% CI -0.7 to 0.1 versus 0.6, 95% CI 0.1 to 1.1) versus
control, as did overall cardiovascular function. However,
there were several methodological flaws in this small trial,
including a failure to measure endotoxin levels in the treat-
ment and control groups and the use of 28-day mortality
as a secondary endpoint. While these findings suggest
the need for larger clinical trials to be performed before
widespread implementation can be recommended, these
preliminary results appear promising.
Although the in vivo animal studies cited above have
shown that broad regulation of cytokine levels is possible
with the use of cytokine-reducing resins, modulation of
cytokine levels by continuous hemodialysis in humans
has not been clearly demonstrated. Despite the very short
half-life of many inflammatory cytokines, small initial
studies suggested that high-volume hemofiltration might
be able to modulate overall cytokine profiles in humans
[40,41]. However, larger randomized controlled trials
failed to show that continuous hemofiltration modulates
cytokine levels [42], nor has any clinical benefit been dem-
onstrated with the use of high-volume hemofiltration in
the treatment of sepsis [42-44]. While the large VA/NIH
Acute Renal Failure Trial Network study showed no mor-
tality difference in the septic subgroup of patients who
underwent more intense renal replacement, subsequent
analysis has shown higher rates of non-recovery of kidney
function and increased mortality in patients with higher
circulating concentrations of pro- and anti-inflammatory
cytokines and apoptosis markers [45]. This result again
suggests that targeting certain subgroups along the immu-
nologic spectrum might be beneficial not only in targeted
cytokine therapy, but also in the broad modulation of in-
flammatory cytokines via hemofiltration and absorption.
Finally, the use of agents to augment immune function
in patients suffering from sepsis-associated immunosup-
pression has shown clinical promise. As mentioned above,
sepsis represents a complex inflammatory state with both
pro- and anti-inflammatory characteristics. Thus, identify-
ing and treating septic patients who are on the more
immunosuppressed spectrum of sepsis with immune
augmentation may improve outcomes. Meisel and associ-
ates [46] administered granulocyte-macrophage colony-
stimulating factors (GM-CSFs) to septic patients who had
decreased monocyte HLA-DR expression and found that
monocyte immunocompetence could be restored in this
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clinical outcomes that were measured (ventilator days and
hospital length of stay), their data showed that biomarker-
guided GM-CSF therapy in sepsis is safe and could hold
promise in larger randomized controlled trials.
Toll-like receptor-4 and the effects of sepsis on renal
epithelial cells
Initial molecular research on sepsis suggested that the
generalized inflammatory state described above is ini-
tiated when the innate immune system recognizes highly
conserved pathogen-associated molecular patterns (PAMPs),
such as LPS [47]. However, in the late 1990s Polly Matzinger
[48] proposed the ‘danger model’, which argues that the
immune system is more concerned with ‘danger signals’
than with foreign signals. Subsequent research has
found that there are numerous ‘damage-associated mo-
lecular patterns’ (DAMPs) that can elicit immune re-
sponses similar to PAMPs [49]. The extent to which
both PAMPs (a subgroup of DAMPs) and more broadly
DAMPs activate the immune system and contribute to
sepsis and septic AKI is not fully understood, but recent
research has provided a significant amount of insight
into the process.
TLRs have provided a link between host and pathogen
[50,51], as well as host and DAMPs [52]. In the 1990s,
TLR-4 was found to be the main receptor that binds
LPS, leading to the release of TNF-α and IL-1 and
activation of numerous downstream intracellular signal-
ing pathways via the NF-κB transcription factor [50,53]
(Figure 1). Additionally, in sterile models of inflamma-
tion, TLR-4 has been shown to respond to DAMPs, such
as high mobility group-B1 [54-56]. Indeed, the capacity
of TLRs to respond to PAMPs as well as other DAMPs
provides a potential link between systemic inflammation
and kidney damage that is independent of ischemia and
hypotension. In the kidney, TLR-4 is constitutively ex-
pressed in mouse primary renal tubular epithelial cells
[57] and in mouse cells harvested from in vivo experi-
ments [58], in renal tubular cells harvested from rats
[59,60], and in human kidney tubular epithelial cells taken
from surgical patients [61]. TLR-4 expression in the
glomeruli is controversial [59,60], but its expression
in tubular epithelial cells has been shown to modulate
septic AKI and inflammation (Figure 1) in multiple
models of injury [60,62,63]. The final downstream
mechanisms that produce AKI after TLR-4 activation
are complex and incompletely understood. Of note,
recent work suggests that one important mechanism
underpinning septic AKI is that this inflammatory path-
way induces renal tubular transport dysfunction,
which enhances NaCl delivery to the macula densa
and increases tubuloglomerular feedback, thus decreasing
GFR [64].NF-κB is a highly expressed transcription factor that is
often activated in response to cellular stresses and
induces the synthesis and release of TNF-α, IL-1, IL-6,
and IL-8 [65]. NF-κB-mediated processes occur in iso-
lated primary rat proximal tubular epithelial cells [66],
but the overall contribution of inflammatory cytokine
levels in the kidney from local versus systemic produc-
tion of those cytokines is unknown. Experiments per-
formed on TLR-4 knockout mice transplanted with
TLR-4 expressing kidneys suggest systemic production
may be more important [62]. Direct inhibition of NF-κB
with agents such as methyl-2-acetamidoacrylate (an ethyl
pyruvate analogue) [67], ethyl pyruvate [68], and nico-
tinic acetylcholine [69] can lower cytokine levels in mice
(TNF-α, IL-6, IFN-γ, and IL-10) and have been associated
with improved clinical characteristics in mice suffering
from septic AKI [67-69].
However, a recent randomized controlled trial examin-
ing the effect of an MD2-TLR-4 antagonist failed to
show any mortality benefit in human patients suffering
from severe sepsis [70]. In this study, none of the patients
enrolled were stratified in terms of what type of infection
they were suffering from (polymicrobial, Gram-positive,
or Gram-negative). Moreover, levels of endotoxin were
not measured, which leaves open the possibility that some
patients may have benefited depending on where they
stood on the immunologic spectrum. Nonetheless, this
trial possibly highlights some of the pitfalls of associating
LPS endotoxemia with human sepsis that have manifested
themselves over the past 20 years in sepsis research.
Indeed, multiple studies have shown that in polymicro-
bial and cecal ligation and puncture models the mechan-
ism of damage induced by sepsis may be very different
than in LPS-induced models [71], might be independent
of TLRs altogether [72-75], and instead could be mediated
by direct MyD88 regulation (Figure 1) [72,75]. Interest-
ingly, the presence of a specific TLR-4 mutation (D299G)
in humans, which impairs LPS signaling, has not been
shown to influence TNF-α, IL-6, and IL-10 levels in sepsis
[73]. Nor has this particular allele been associated with
any change in outcome or development of sepsis in
patients undergoing major visceral surgery [73] or in pa-
tients with meningococcal disease [76]. The effect of this
specific mutation has not been examined in kidneys dir-
ectly, and its study may provide significant insight into the
mechanisms of septic AKI in humans. Of note, the use of
various mouse models to study human inflammation
and sepsis has recently been questioned due to the
significant differences in the two species’ genomic re-
sponses to stress [77].
Does apoptosis have a role in septic acute kidney injury?
The traditional model of apoptosis in kidney and other
cells is similar [78]. Processes involving the mitochondria
Figure 1 Schematic illustration of the activation of the NF-κB transcription factor pathway by liposaccharide (LPS), TNF-α, high mobility
group (HMG)B1, and polymicrobial sepsis. LPS binding to Toll-like receptor-4 (TLR-4) is dependent on its interaction with circulating LPS-binding
protein (LBP) and the subsequent interplay of this complex to membrane bound CD14 [90]. This LPS-LBP-CD14-TLR-4 complex is thus anchored to
various cells within the kidney (especially within the apical brush border of proximal tubules) [60], where it initiates intracellular signaling cascades.
CD14 gene expression is upregulated by LPS [91] in human kidney proximal tubular epithelial cells and by TNF-α [92] in mouse renal interstitial and
tubular epithelial cells. Activated TLR-4 via LPS stimulates the MyD88 pathway [47,93,94], and ultimately induces phosphorylation of IκB by IκB-kinase-β
(IKKβ; tan-colored) within the IKK complex [65]. Phosphorylated IκB is then released from NF-κB, allowing NF-κB to migrate to the nucleus to modulate
transcription of various cytokines as shown. HMGB1 activation of TLR-4 activates NF-κB via an alternative mechanism whereby both IKKα and IKKβ
(tan-colored) are implicated [54,55]. In cecal ligation and puncture models of sepsis, MyD88 has been shown to be activated independent of TLR-4 by
unknown upstream cell surface receptors [72,75]. IRAK, interleukin receptor-associated kinase; MAPK, p38 mitogen-activated protein kinase; TRAF,
TNF receptor associated factor.
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cell surface proteins leading to subsequent intracellular
signaling events are termed ‘extrinsic’ processes (Figure 2)
[78]. However, the mechanisms whereby cells in the septic
kidney succumb (or do not succumb) to apoptosis are still
under investigation. One important route may be via
the tumor necrosis factor receptor-1 (TNFR-1; Figure 2).
TNFR-1 knockout mice were resistant to LPS-induced
kidney failure while they also manifested much less apop-
tosis and neutrophil accumulation, suggesting a direct role
for both necrosis and apoptosis in septic AKI [79]. Down-
stream of TNFR-1, Jo and colleagues [80] have shown that
apoptosis in LPS, TNF-α, and IL-1 exposed HK-2 cells islikely dependent in part on Fas and caspase expression.
Caspase inhibition has also been shown to prevent apop-
totic proximal, distal, and peri-tubular cell death in LPS
models of septic AKI [81]. Cantaluppi and associates
[38] have demonstrated a role for the Fas and caspase-
mediated pathway in septic AKI as well. Using primary
human proximal tubule epithelial cells exposed to septic
human plasma, they showed that: 1) apoptosis as detected
through DNA TUNEL assays was significantly increased
in cells exposed to septic plasma; 2) levels of Fas and
caspase-3, -8, and -9 were all significantly increased in
response to septic plasma; and 3) levels of those effector
signals and apoptosis can be decreased by removal of
Figure 2 Schematic illustration of the molecular processes leading to apoptosis in renal proximal tubular epithelial cells. So-called death
receptors such as Fas, TNF receptor-1 (TNFR-1), or the TNF-related apoptosis-inducing ligand (TRAIL) receptors bind with extracellular ligands to
activate downstream activator caspases [78]. This process is usually mediated by the FADD (Fas-associated protein with death domain) receptor,
and ultimately activates caspase-3 - the effector molecule. Within the cell, the intrinsic pathway is initiated via cellular stresses: reactive oxygen
species (ROS), nitric oxide, decreased ATP, or cell-cell/cell-matrix perturbations [95]. In response to those stresses, BAX migrates into the mitochondria
via activation from BH3-only proteins within the Bcl-2 family [96]. Once they have entered the mitochondria, BAX and other pro-apoptotic proteins form
pores within the mitochondrial wall, allowing for the release of cytochrome c, which triggers caspase-dependent and -independent pathways [95].
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filter septic plasma [38]. Indeed, initiation of apoptosis
was observed in cultured kidney tubular cells exposed to
plasma taken from patients suffering from severe burns
and septic AKI [82].
However, in most of the in vitro and in vivo studies
examining the presence or role of apoptosis in septic
AKI, there were major methodological shortcomings.
LPS was used as a model for sepsis in most of the studies
cited above [79-81], as well as many experiments evaluat-
ing kidney tubular apoptosis in primary mouse distal
convoluted tubule cells [83] and mouse MCT proximal
tubule cells [84]. As mentioned in the previous section,
LPS endotoxemia is not a model of sepsis. Perhaps even
more confounding to the argument that apoptosis is a
major factor in septic AKI is the lack of histological evi-
dence in patients with septic AKI. Histologic sections of
septic human kidneys generally demonstrate very little
necrosis or cell damage [5-8]. Moreover, a significant
amount of data taken from ‘warm’ autopsies [5,8] has alsofailed to show substantial apoptosis, at least as measured
by conventional light microscopy [5], electron microscopy
[8], and DNA agarose gel electrophoresis for apoptotic
laddering [5]. In the seminal septic autopsy study perfor-
med by Hotchkiss and colleagues [5], they failed to ob-
serve any evidence of kidney apoptosis despite the fact
that 65% of their samples were taken from patients with
clinically manifest sepsis-associated kidney dysfunction.
While apoptosis likely plays a major role in lymphocytes
and other cells within the human body during sepsis [30],
its role in septic AKI is unclear. Further study using more
physiologically relevant models of sepsis (as opposed to
LPS) are needed to help reconcile much of the conflicting
data that currently exist.
Perhaps one of the reasons for the discrepancy between
histologic data and functional performance in septic AKI
is that most of the insults occur prior to significant cell
death from apoptosis and necrosis. Indeed, apoptosis and
necrosis are end-stage manifestations of cellular insults,
and significant impairment of cellular function can occur
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sured in most apoptosis and necrosis assays. Despite a
measured decrease in kidney perfusion in their septic
mouse model, Tran and associates found no elevation in
hypoxia-inducible factor-1α, a transcription factor that is
significantly upregulated [85] in hypoxic and ischemic rat
kidneys [86]. They hypothesized that this was due to
significantly reduced oxygen consumption by kidney
proximal tubule cells during sepsis [86]. Further study
showed that this process was likely mediated by PPARγ
coactivator-1α (PGC-1α), a major regulator of mitochon-
drial function. PGC-1α was significantly downregulated in
septic rats exposed to LPS and TNF-α, whereas increased
levels of PGC-1α were associated with restored oxygen
consumption and improved kidney function [86]. While
increased expression of hypoxia-inducible factor-1α was
not seen in mice exposed to LPS [86], sepsis has been
associated with significant intra-renal oxidative and nitro-
sative stress that is mediated by inflammatory cytokines
rather than local hypoxia or ischemia [87,88]. The idea of
‘cellular stunning’, whereby a cell that is living within a
septic environment is trying to defend itself from death by
decreasing its metabolic activity, has been proposed as a
mechanism not only in sepsis by Hotchkiss and Karl [30],
but also in ischemic models in the heart [89].
Conclusion
While the relative contributions that ischemia, TLR-4-
mediated pathways, apoptosis, and other subcellular
processes have towards overall organ dysfunction are
currently unclear, the abundance of research in the area
has shed a significant amount of light on the basic mecha-
nisms that drive septic AKI. Perhaps the most important
finding is that therapeutic approaches targeted at a single
mediator for all patients may not succeed given the pro-
tean nature of the disease. Indeed, targeted inhibition of
cytokines such as TNF-α and IL-1 as well as TLR antago-
nists have failed to show consistent and significant clinical
benefit, most likely because only certain subsets of septic
patients fit an immunologic profile that would benefit
from those therapies. An important next step in sepsis
research should be to identify immunologic markers in
patients that can help tailor specific therapies for patients
based on where they lie along the immunologic spectrum.
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